Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 17 Saturday Friday Sunday Monday Tuesday Publication Only MONDAY, JUNE 3 RD 1:30pm - 4:30pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 1:30 - 4:30pm Hall A Poster TPS8128 Alisertib in patients with extensive- stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study. Owonikoko T Wang B Lung Cancer—Non- Small Cell Local- Regional/Small Cell/ Other Thoracic Cancers 3:00 - 4:00pm 3:00 - 3:40pm Hall D2 Oral Panelist Subbiah V Beyond Tumor Types: Advancing Tumor-Agnostic Drug Development and the Role of the Tumor Microenvironment 3:00 - 4:00pm 3:00 - 3:40pm Hall D2 Oral Panelist McKenzie A Beyond Tumor Types: Advancing Tumor-Agnostic Drug Development and the Role of the Tumor Microenvironment 3:00 - 6:00pm 5:00 - 5:12pm Hall B1 Oral 506 Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer. Cobain E Osborne C, O'Shaughnessy J Breast Cancer—Local/ Regional/Adjuvant TUESDAY, JUNE 4 TH 8:00am - 12:45pm Central Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 8:00 - 9:15am 8:30 - 8:45am S100a Oral Emerging Data for Antibody Drug Conjugates in Head and Neck Squamous Cell Carcinoma Perez C Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD- L1 Immunotherapy 9:45 - 11:15am 10:57 - 11:03am S102 Oral 7517 Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM). van de Donk N Matous J Hematologic Malignancies—Plasma Cell Dyscrasia 9:45am - 12:45pm 10:57 - 11:09am S100a Oral 6004 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). Colevas A Jotte R Head and Neck Cancer 9:45am - 12:45pm 11:09 - 11:21am S100a Oral 6005 HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results. Ho A Naqash A Head and Neck Cancer